首页> 外文期刊>Drug delivery. >Modified nanoparticles with cell-penetrating peptide and amphipathic chitosan derivative for enhanced oral colon absorption of insulin: preparation and evaluation
【24h】

Modified nanoparticles with cell-penetrating peptide and amphipathic chitosan derivative for enhanced oral colon absorption of insulin: preparation and evaluation

机译:具有细胞穿透肽和两亲性壳聚糖衍生物的改性纳米颗粒可增强口服结肠对胰岛素的吸收:制备和评价

获取原文
           

摘要

Abstract Colon is an ideal absorptive site for oral protein and peptide drug (insulin), and yet it poses multiple barriers against the drug absorption, such as the barriers against the drug diffusion from colon lumen toward the absorptive mucosa and permeation across colon epithelium. In this study, modified nanoparticles (Tat-CS-NPs) with cell-penetrating peptide (Tat) and amphipathic chitosan derivative (a-CS) were used as carriers to improve colonic absorption of the drug. With a-CS as emulsifier and poly(lactic-co-glycolic acid) as matrix material, Tat-CS-NPs were prepared and evaluated in vitro/vivo. Using Caco-2 cell monolayers to imitate the colonic epithelial cells, it was found that the cellular uptake amount and transcellular transportation performance of Tat-CS-NPs were much enhanced compared with those of CS-NPs and PVA-NPs. The efficacy evaluation on diabetic rat models demonstrated that the hypoglycemic effect of Tat-CS-NPs loaded with insulin was 6.89 times higher than that of PVA-NPs, and 1.79 times higher than that of CS-NPs. By gavage of [99mTc] isotope labeled Tat-CS-NPs in mini-pigs and single-photon emission computed tomography (SPECT) on pigs' gastrointestinal tract, it was further proved that the nanoparticles could reach colon and produce pharmacological effect. In conclusion, Tat-CS-NPs as vehicles for colon-specific drug delivery may be an efficient approach to improve oral bioavailability of protein and peptide drugs.
机译:摘要结肠是口服蛋白质和肽类药物(胰岛素)的理想吸收位点,但它对药物的吸收构成了多种障碍,例如,阻碍药物从结肠腔向吸收性粘膜扩散和渗透到结肠上皮的障碍。在这项研究中,具有细胞穿透肽(Tat)和两亲性壳聚糖衍生物(a-CS)的修饰纳米颗粒(Tat-CS-NPs)被用作载体,以改善药物的结肠吸收。以α-CS为乳化剂,聚乳酸-乙醇酸为基质材料,制备了Tat-CS-NPs并进行了体外/体内评价。使用Caco-2细胞单层模拟结肠上皮细胞,发现与CS-NP和PVA-NP相比,Tat-CS-NP的细胞摄取量和跨细胞运输性能大大提高。对糖尿病大鼠模型的功效评估表明,载有胰岛素的Tat-CS-NPs的降血糖作用比PVA-NPs高6.89倍,比CS-NPs高1.79倍。通过对小型猪中[ 99m Tc]同位素标记的Tat-CS-NPs的灌胃和猪胃肠道的单光子发射计算机断层扫描(SPECT),进一步证明了纳米颗粒可以达到结肠并产生药理作用。总之,Tat-CS-NP作为结肠特异性药物输送的载体可能是提高蛋白质和肽类药物口服生物利用度的有效方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号